STAT4-mediated miR-3619-5p controls the onset and progression of STAD by regulating TBC1D10B expression, and STAD patients with high STAT4 expression are predicted to have better clinical outcomes [62, 63]. This evidence concerns the gene STAT4 and gastric adenocarcinoma.